|Bid||5.24 x 1600|
|Ask||10.53 x 500|
|Day's Range||5.38 - 5.57|
|52 Week Range||4.85 - 7.78|
|PE Ratio (TTM)||-17.54|
|Earnings Date||Apr 26, 2017 - May 1, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
LA JOLLA, Calif., June 05, 2017-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that Associate Professor ...
There have been a number of recent announcements regarding MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS), which is a rapidly progressing neurodegenerative disease whereby the nerve cells in the brain and spinal cord that control muscle movement degenerate. - On February 7, 2017, MediciNova, Inc. (MNOV) announced that an abstract regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) will be presented at the American Academy of Neurology (AAN) 69th Annual Meeting, which is taking place from Apr. 22-28, 2017 in Boston, Massachusetts. - On December 20, 2016, MediciNova announced that the European Commission has granted Orphan Medicinal Product Designation (OMPD) for MN-166 for the treatment of ALS.
On December 19, 2016, MediciNova, Inc. (MNOV) announced that the Data and Safety Monitoring Board (DSMB) for the ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS) reviewed the results of the interim efficacy analysis and recommended to the National Institute of Neurological Diseases and Stroke (NINDS) that the trial should continue as planned, to which the NINDS has agreed. Thus, the fact that the DSMB recommended that the trial continue as planned is indicative that there is at least a positive trend in the direction of efficacy for MN-166. If there was no trend in favor of MN-166, the trial would have been stopped for futility.